PATE	MI 25 ZOTE	
13	PADEMARK OFFICE	

\*EXAMINER INITIAL

LIST OF REFERENCES CITED BY APPLICANT

DOCUMENT NUMBER

(Use several sheets if necessary)

DATE

EXPRESS MAIL NO.: <u>EV 335 856 295 US</u> Sheet 1 of 1 ATTY DOCKET NO. APPLICATION NO 5914-080-999 09/305,084 APPLICANT Schneider and Jamal FILING DATE GROUP 1642 May 4, 1999 **U.S. PATENT DOCUMENTS** FILING DATE
IF APPROPRIATE NAME CLASS SUBCLASS

## FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO

<del></del>	[ 67	Adnes et al. 1004 Whenever adultable PT
KAC	C01	Adner et al., 1994, "Human endothelin ET <sub>A</sub> receptor antisense oligodeoxynucleotides inhibit endothelin-1 evoked vasoconstriction", Eur. J. Pharm. 261:281-284.
	C02	Barber et al., 1996, "Chronic increases in blood flow upregulate endothelin-B receptors in arterial smooth muscle", Am. J. Physiol. 270:H65-H71.
	C03	Battistini and Dussault, 1998, "Blocking of the endothelin system: the development of receptor antagonists", Pul. Pharm. Therap. 11:97-112.
	C04	Chan et al., 1998, "The discovery and structure-activity relationships of nonpeptide, low molecular weight antagonist selective for the endothelin ET <sub>B</sub> receptor", <i>Bioorganic &amp; Medicinal Chemistry</i> 6:2301-2316.
	C05 °	Davenport and Battistini, 2002, "Classification of endothelin receptors and antagonists in clinical development", Clinical Science 103:1S-3S.
	C06 °	D'Orléans-Juste et al., 1997, "DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors", Molec. Cell. Biochemistry 172:199-211.
	C07-3	Douglas, 1997, "Clinical development of endothelin receptor antagonists", TiPS 18:408-412.
	C08	Mederski et al., 1999, "Benzofuro[3,2-b] Pyridines as mixed ET <sub>A</sub> /ET <sub>B</sub> and selective ET <sub>B</sub> endothelin receptor antagonists", Bioorg. Med. Chem. Lett. 9:619-622.
V	C09 <sup>4</sup>	Ninomiya et al., 1998, "Paracrine endothelin signaling in the control of basal cell proliferation in guinea pig tracheal epithelium", J. Pharmacol. Exp. Therap. 286:469-480.

EXAMINER John A. Ganella	DATE CONSIDERED 3/1/04				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					